PubHawk
November 2009 PMID 19880844

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, Mark E Cooper, Dick de Zeeuw, Kai-Uwe Eckardt, Jan M Feyzi, Peter Ivanovich, Reshma Kewalramani, Andrew S Levey, Eldrin F Lewis, Janet B McGill, John J V McMurray, Patrick Parfrey, Hans-Henrik Parving

Full text PDF Download social card

Mentions

31
Peak: 6 in Jan 2019
across 6 sources since Feb 2016

Extended reach

76,468
potential audience

Total likes

68

Video views

3,741

Mentions per month

Feb 2016 – Apr 2024

Where it's discussed

  • X / Twitter12 posts
  • News8 articles
  • Blogs6 articles
  • YouTube2 videos
  • Facebook2 posts
  • Bluesky1 posts

AI synopsis

What people are saying

The discussions reflect targeted analysis of the TREAT trial, emphasizing findings like increased stroke risk and no benefit on cardiovascular outcomes, using terms like 'higher stroke events' and 'no improvements,' which show thoughtful engagement and concern for clinical impact.

AgreementModerate agreement

Most discussions acknowledge the findings of the TREAT trial, emphasizing the lack of benefits and potential risks of darbepoetin alfa.

InterestModerate interest

The social discussions show moderate interest, referencing detailed trial outcomes, stroke risks, and hemoglobin levels.

EngagementModerate engagement

Participants analyze the data, referencing specific results such as hazard ratios and trial design, indicating moderate depth of engagement.

ImpactModerate impact

There is recognition of the trial's significance, particularly around clinical implications for CKD management and anemia treatment guidelines.

Abstract in brief

  • Anemia increases cardiovascular and renal risks in patients with type 2 diabetes and chronic kidney disease, but the effect of darbepoetin alfa on clinical outcomes is unclear.
  • A study with 4038 patients randomly assigned them to receive either darbepoetin alfa or placebo, focusing on death and cardiovascular events as primary outcomes.
  • Results showed no significant advantage for darbepoetin alfa in reducing risks of death or cardiovascular events, although there was a higher incidence of strokes and a slight increase in patient-reported fatigue compared to those on placebo.
Read the full abstract

Top posts

Most liked on X and Bluesky
Tejas Desai, MD, MBA
@nephondemand · X

• TREAT https://t.co/mt1Ig8tO2L Randomized placebo trial of Darbepoetin. Two Hemoglobin groups: ~ 12.5 g/dl v 10.0- 11.5 g/dl. No improvements in cardiovascular outcomes with Darbepoetin. Preponderance of data suggests target hemoglobin in advanced CKD should be 10-11.5 #meded https://t.co/hhLfnR0CEo

Jan 16, 2019 · 5 likes · 6 shares · 11,974 followers View post →
Nephrology Journal Club
@NephJC · X

T0: Now let’s see what the TREAT Trial showed us: The Darbapoetin group had higher stroke events and higher venous and arterial thromboembolic events compared to the placebo group #NephJC https://t.co/IfCfUnbZEs https://t.co/tFP1wZj3Zh

Feb 24, 2021 · 4 likes · 1 share · 38,535 followers View post →
KIReports
@KIReports · X

TREAT (c. 2009) 4000 CKD patients.

Oct 19, 2021 · 3 likes · 13,747 followers View post →
@CKD_ce
@ckd_ce · X

28) The largest of these #RCTs, #TREAT, used #darbepoetin to target Hgb of 13 g/dL in the intervention group (vs. 9 g/dL in placebo). It showed that higher Hgb targets were associated with ✅No effect on CV or renal outcomes ⬆️Risk of stroke

Nov 22, 2022 · 3 likes · 2,645 followers View post →
Karen Dwyer
@KarenDwyer12 · X

RT @nephondemand: • TREAT https://t.co/mt1Ig8tO2L Randomized placebo trial of Darbepoetin. Two Hemoglobin groups: ~ 12.5 g/dl v 10.0- 11.5…

Jun 1, 2019 · 6 shares · 1,989 followers View post →
Luis Enrique Alvarez
@LuisAlvarezRa · X

RT @nephondemand: • TREAT https://t.co/mt1Ig8tO2L Randomized placebo trial of Darbepoetin. Two Hemoglobin groups: ~ 12.5 g/dl v 10.0- 11.5…

Jan 16, 2019 · 6 shares · 911 followers View post →

All mentions

@CKD_ce
@ckd_ce · X

28) The largest of these #RCTs, #TREAT, used #darbepoetin to target Hgb of 13 g/dL in the intervention group (vs. 9 g/dL in placebo). It showed that higher Hgb targets were associated with ✅No effect on CV or renal outcomes ⬆️Risk of stroke

Nov 22, 2022 · 3 likes · 2,645 followers View post →
KIReports
@KIReports · X

TREAT (c. 2009) 4000 CKD patients.

Oct 19, 2021 · 3 likes · 13,747 followers View post →
linhdtu
@tuduylinh · X

@beauregard2 And why not? look up CV for epo. here is Aranesp:Fatal or nonfatal stroke occurred in 101 patients assigned to darbepoetin alfa and 53 patients assigned to placebo (hazard ratio, 1.92; 95% CI, 1.38 to 2.68; P<0.001). https://t.co/8RFHcJts8Z

Apr 7, 2021 · 351 followers View post →
Augusto Cesar S Santos Jr
@acssjr · X

RT @NephJC: T0: Now let’s see what the TREAT Trial showed us: The Darbapoetin group had higher stroke events and higher venous and arterial…

Feb 24, 2021 · 1 share · 877 followers View post →
Nephrology Journal Club
@NephJC · X

T0: Now let’s see what the TREAT Trial showed us: The Darbapoetin group had higher stroke events and higher venous and arterial thromboembolic events compared to the placebo group #NephJC https://t.co/IfCfUnbZEs https://t.co/tFP1wZj3Zh

Feb 24, 2021 · 4 likes · 1 share · 38,535 followers View post →
Karen Dwyer
@KarenDwyer12 · X

RT @nephondemand: • TREAT https://t.co/mt1Ig8tO2L Randomized placebo trial of Darbepoetin. Two Hemoglobin groups: ~ 12.5 g/dl v 10.0- 11.5…

Jun 1, 2019 · 6 shares · 1,989 followers View post →
FOAM Cards
@FOAM_Cards · X

(1/2)Trial of the day: TREAT Pfeffer MA, et al. "A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease". The New England Journal of Medicine. 2009. 361(21):2019-32. https://t.co/eHHhNzYPzv #FOAMcards

Jan 29, 2019 · 67 followers View post →
Dr Theepa N.M.R
@TNesam · X

RT @nephondemand: • TREAT https://t.co/mt1Ig8tO2L Randomized placebo trial of Darbepoetin. Two Hemoglobin groups: ~ 12.5 g/dl v 10.0- 11.5…

Jan 27, 2019 · 6 shares · 698 followers View post →
madree
@madrees007 · X

RT @nephondemand: • TREAT https://t.co/mt1Ig8tO2L Randomized placebo trial of Darbepoetin. Two Hemoglobin groups: ~ 12.5 g/dl v 10.0- 11.5…

Jan 21, 2019 · 6 shares · 53 followers View post →
Roberto Pineda
@ROPPINEDA · X

RT @nephondemand: • TREAT https://t.co/mt1Ig8tO2L Randomized placebo trial of Darbepoetin. Two Hemoglobin groups: ~ 12.5 g/dl v 10.0- 11.5…

Jan 17, 2019 · 6 shares · 804 followers View post →
Luis Enrique Alvarez
@LuisAlvarezRa · X

RT @nephondemand: • TREAT https://t.co/mt1Ig8tO2L Randomized placebo trial of Darbepoetin. Two Hemoglobin groups: ~ 12.5 g/dl v 10.0- 11.5…

Jan 16, 2019 · 6 shares · 911 followers View post →
Tejas Desai, MD, MBA
@nephondemand · X

• TREAT https://t.co/mt1Ig8tO2L Randomized placebo trial of Darbepoetin. Two Hemoglobin groups: ~ 12.5 g/dl v 10.0- 11.5 g/dl. No improvements in cardiovascular outcomes with Darbepoetin. Preponderance of data suggests target hemoglobin in advanced CKD should be 10-11.5 #meded https://t.co/hhLfnR0CEo

Jan 16, 2019 · 5 likes · 6 shares · 11,974 followers View post →
Joel Topf
@kidneyboy.bsky.social · Bluesky

#NephJCclassics 2 ESA anemia classics: Beserab and TREAT http://www.nejm.org/doi/full/10.1056/NEJMoa0907845 http://www.nejm.org/doi/full/10.1056/NEJM199808273390903

Feb 16, 2016 View post →